Gyros Protein Technologies Signs Distribution Agreement with Euro Diagnostica
News Oct 12, 2017
Gyros Protein Technologies AB announced it has signed a distribution agreement with Euro Diagnostica. The agreement will give Gyros Protein Technologies’ customers in Europe and North America direct access to the iLite® assay ready cell lines from Euro Diagnostica, which help overcome limitations of conventional cell-based assays and improve productivity.
The iLite technology is based upon a unique reporter gene assay format, modified and adapted for applications through the whole drug development cycle as well as for monitoring of biological drugs. The applications addressed by iLite reporter gene assays are highly complementary to those addressed by Gyros Protein Technologies’ Gyrolab™ immunoassays systems, such as pharmacokinetics studies, detection of ADA (anti-drug antibodies) and bioprocess applications. The iLite dual reporter gene format allows for normalization of the response, eliminating unwanted matrix effects and compensating for differences in cell numbers, to achieve accurate and biologically relevant results. The cells are delivered frozen and assay ready, requiring no culture or maintenance, to enable cost reductions and time savings.
iLite assays have been designed to support screening of drug candidates, detection of neutralizing antibodies (NAb) as part of immunogenicity assessment, and potency measurements in manufacturing release tests. NAb are a subset of anti-drug antibodies (ADA) that bind to the therapeutic molecule resulting in its inhibition or complete neutralization, and affect the clinical efficacy of the drug. Detection and elimination of NAb is key to reducing the potential patient side effects of these unwanted drug components. The FDA recommends the use of cell-based neutralization assays over ligand-binding formats, when appropriate, as these more frequently provide physiologically relevant results.
Phenogenetic Map Created For Stem Cell Models Of Neurological DiseasesNews
Researchers at The Ohio State University Wexner Medical Center have performed the first meta-analysis of all induced pluripotent stem cell models for neurological and neurodegenerative diseases, and created an atlas of how cell characteristics are linked to their genotype.READ MORE
Fabric Genomics Partners to Improve Pediatric CareNews
Partnerships with Genomics England, Rady Children's Institute for Genomic Medicine, and The Utah Genome Project demonstrate diagnostic utility of Fabric Genomics' algorithm-based genome analysis.READ MORE
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE